Connie Marras

Summary

Affiliation: University of Toronto
Country: Canada

Publications

  1. ncbi Antipsychotic use in older adults with Parkinson's disease
    Connie Marras
    Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, University Health Network, Toronto, Canada
    Mov Disord 22:319-23. 2007
  2. ncbi Pergolide associated cardiac valvulopathy based on Ontario administrative data
    Cindy Zadikoff
    Morton and Gloria Shulman Movement Disorders Center, Toronto Western Hospital, Department of Neurology, Toronto, Ontario, Canada
    Can J Neurol Sci 35:173-8. 2008
  3. doi A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts
    Connie Marras
    Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada
    Mov Disord 24:2370-8. 2009
  4. doi LRRK2 and Parkin mutations in a family with parkinsonism-Lack of genotype-phenotype correlation
    Connie Marras
    Movement Disorders Centre, Toronto Western Hospital, Toronto, Canada
    Neurobiol Aging 31:721-2. 2010
  5. ncbi Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial
    Connie Marras
    Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Mov Disord 23:653-9; quiz 776. 2008
  6. doi Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts
    Connie Marras
    Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada
    Mov Disord 26:608-13. 2011
  7. ncbi Outcome measures for clinical trials in Parkinson's disease: achievements and shortcomings
    Connie Marras
    Toronto Western Hospital, Movement Disorders Centre, 7 McLaughlin, 399 Bathurst Street, Toronto, ON M5T 2S8, Canada
    Expert Rev Neurother 4:985-93. 2004
  8. ncbi Smell identification ability in twin pairs discordant for Parkinson's disease
    Connie Marras
    The Parkinson s Institute, Sunnyvale, California, USA
    Mov Disord 20:687-93. 2005
  9. ncbi Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort
    C Marras
    Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Ontario, Canada M5T 2S8
    Neurology 64:87-93. 2005
  10. pmc Genetic modification of the association of paraquat and Parkinson's disease
    Samuel M Goldman
    The Parkinson s Institute, Sunnyvale, California 94085, USA
    Mov Disord 27:1652-8. 2012

Collaborators

Detail Information

Publications40

  1. ncbi Antipsychotic use in older adults with Parkinson's disease
    Connie Marras
    Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, University Health Network, Toronto, Canada
    Mov Disord 22:319-23. 2007
    ..Typical antipsychotics are still commonly being chosen as first-line agents for older patients, indicating a need for interventions to improve practice...
  2. ncbi Pergolide associated cardiac valvulopathy based on Ontario administrative data
    Cindy Zadikoff
    Morton and Gloria Shulman Movement Disorders Center, Toronto Western Hospital, Department of Neurology, Toronto, Ontario, Canada
    Can J Neurol Sci 35:173-8. 2008
    ....
  3. doi A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts
    Connie Marras
    Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada
    Mov Disord 24:2370-8. 2009
    ..This may relate to changes in philosophies with respect to starting treatment for Parkinson's disease, but the factors underlying this change remain to be elucidated...
  4. doi LRRK2 and Parkin mutations in a family with parkinsonism-Lack of genotype-phenotype correlation
    Connie Marras
    Movement Disorders Centre, Toronto Western Hospital, Toronto, Canada
    Neurobiol Aging 31:721-2. 2010
    ..In the combined mutation carriers the age at onset and clinical course was highly variable and not always younger than in the carriers of LRRK2 G2019S mutations alone...
  5. ncbi Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial
    Connie Marras
    Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Mov Disord 23:653-9; quiz 776. 2008
    ..Our focus in clinical care needs to be broadened beyond assessing and treating Parkinsonism, recognizing the impact of mood, cognition and function on HRQOL...
  6. doi Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts
    Connie Marras
    Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada
    Mov Disord 26:608-13. 2011
    ..We suspect that individuals employed full time may have a lower threshold for requiring dopaminergic therapy because of occupational demands...
  7. ncbi Outcome measures for clinical trials in Parkinson's disease: achievements and shortcomings
    Connie Marras
    Toronto Western Hospital, Movement Disorders Centre, 7 McLaughlin, 399 Bathurst Street, Toronto, ON M5T 2S8, Canada
    Expert Rev Neurother 4:985-93. 2004
    ..Currently, neuroimaging techniques that reflect function of the dopaminergic system are the most promising biomarkers but still require additional validation...
  8. ncbi Smell identification ability in twin pairs discordant for Parkinson's disease
    Connie Marras
    The Parkinson s Institute, Sunnyvale, California, USA
    Mov Disord 20:687-93. 2005
    ..Smell identification ability may not be a sensitive indicator of future PD 7 or more years before the development of motor signs, even in a theoretically at-risk population...
  9. ncbi Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort
    C Marras
    Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Ontario, Canada M5T 2S8
    Neurology 64:87-93. 2005
    ..To investigate predictors of survival in Parkinson disease (PD)...
  10. pmc Genetic modification of the association of paraquat and Parkinson's disease
    Samuel M Goldman
    The Parkinson s Institute, Sunnyvale, California 94085, USA
    Mov Disord 27:1652-8. 2012
    ..GSTT1*0 is common and could potentially identify a large subpopulation at high risk of PD from oxidative stressors such as paraquat...
  11. pmc Solvent exposures and Parkinson disease risk in twins
    Samuel M Goldman
    The Parkinson s Institute, 675 Almanor Avenue, Sunnyvale, CA 94085, USA
    Ann Neurol 71:776-84. 2012
    ..We tested the hypothesis that exposure to specific solvents is associated with PD risk using a discordant twin pair design...
  12. doi Atypical antipsychotic use and parkinsonism in dementia: effects of drug, dose, and sex
    Connie Marras
    Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada
    Am J Geriatr Pharmacother 10:381-9. 2012
    ..There is a particular paucity of information on this in real-world use of these drugs, outside of clinical trial settings...
  13. doi Antipsychotics and mortality in Parkinsonism
    Connie Marras
    Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, ON, Canada
    Am J Geriatr Psychiatry 20:149-58. 2012
    ..The use of antipsychotic medications is associated with an increased risk of death in older adults with dementia. The risk of death in patients with preexisting parkinsonism who receive antipsychotic drugs is not known...
  14. pmc Head injury, α-synuclein Rep1, and Parkinson's disease
    Samuel M Goldman
    The Parkinson s Institute, Sunnyvale, CA 94085, USA
    Ann Neurol 71:40-8. 2012
    ..To test the hypothesis that variability in SNCA Rep1, a polymorphic dinucleotide microsatellite in the promoter region of the gene encoding α-synuclein, modifies the association between head injury and Parkinson's disease (PD) risk...
  15. doi Measuring mild cognitive impairment in patients with Parkinson's disease
    Connie Marras
    Toronto Western Hospital Movement Disorders Centre and the Edmond J Safra Program in Parkinson s Research, Toronto, Ontario, Canada
    Mov Disord 28:626-33. 2013
    ..Other tests recommended by the Task Force Level 1 criteria may represent better choices, and these should be the subject of future research...
  16. ncbi New thyroxine treatment in older adults beginning lithium therapy: implications for clinical practice
    Kenneth I Shulman
    Dept of Psychiatry and the Institute for Clinical Evaluative Sciences, Sunnybrook and Women s College Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada
    Am J Geriatr Psychiatry 13:299-304. 2005
    ....
  17. doi Management of neuropsychiatric symptoms in long-term care residents with Parkinson's disease: a retrospective cohort study
    Nathan Herrmann
    Department of Psychiatry, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
    Drugs Aging 30:19-22. 2013
    ....
  18. doi Impact of mild cognitive impairment on health-related quality of life in Parkinson's disease
    William Reginold
    Toronto Western Hospital, Toronto, Ont, Canada
    Dement Geriatr Cogn Disord 36:67-75. 2013
    ..To assess the impact of mild cognitive impairment (MCI) or cognitive decline on health-related quality of life (HR-QOL) in Parkinson's disease (PD)...
  19. ncbi Atypical antipsychotics and parkinsonism
    Paula A Rochon
    Institute for Clinical Evaluative Sciences, Kunin Lunenfeld Applied Research Unit, Baycrest Centre for Geriatric Care, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    Arch Intern Med 165:1882-8. 2005
    ..This has not been well documented. We compared the risk of development of incident parkinsonism among older adults dispensed atypical relative to typical antipsychotics...
  20. doi Dihydropyridine calcium channel blockers and the progression of parkinsonism
    Connie Marras
    Division of Neurology, Toronto Western Hospital, and University of Toronto, Toronto, Ontario, Canada
    Ann Neurol 71:362-9. 2012
    ..A study was undertaken to test the association between dihydropyridine calcium channel blocker use and the time to important milestones of disease progression among patients with parkinsonism...
  21. doi Occupation and risk of parkinsonism: a multicenter case-control study
    Caroline M Tanner
    Department of Clinical Research, The Parkinson s Institute, Sunnyvale, California 94085, USA
    Arch Neurol 66:1106-13. 2009
    ..We examined risk of parkinsonism in occupations (agriculture, education, health care, welding, and mining) and toxicant exposures (solvents and pesticides) putatively associated with parkinsonism...
  22. ncbi Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations
    Connie Marras
    Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Mov Disord 19:22-8. 2004
    ..We conclude that motor complications that occur within the first 4 years of treatment of PD do not have a significant negative effect on quality of life as measured by a visual analogue scale for most patients...
  23. pmc Rotenone, paraquat, and Parkinson's disease
    Caroline M Tanner
    The Parkinson s Institute, Sunnyvale, California 94085, USA
    Environ Health Perspect 119:866-72. 2011
    ..Certain pesticides may affect these mechanisms, but no pesticide has been definitively associated with PD in humans...
  24. doi Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic
    Margarita Pondal
    Movement Disorders Centre, Toronto Western Hospital, University of Toronto, Canada
    J Neurol Neurosurg Psychiatry 84:130-5. 2013
    ....
  25. doi The pill questionnaire in a nondemented Parkinson's disease population
    William Reginold
    Toronto Western Hospital Movement Disorders Centre, and the Edmond J Safra Program in Parkinson s Disease, Toronto, Ontario, Canada
    Mov Disord 27:1308-11. 2012
    ..However, inaccurate medication reporting is associated with deficits spanning many cognitive domains and should alert a clinician to a higher likelihood of cognitive impairment...
  26. doi The curious case of phenocopies in families with genetic Parkinson's disease
    Christine Klein
    Morton and Gloria Shulman Movement Disorders Center and the Edmond J Safra Program in Parkinson s Disease, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada
    Mov Disord 26:1793-802. 2011
    ....
  27. pmc Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study
    Sudeep S Gill
    Institute for Clinical Evaluative Sciences, 2075 Bayview Avenue, Toronto, ON, Canada
    BMJ 330:445. 2005
    ..To compare the incidence of admissions to hospital for stroke among older adults with dementia receiving atypical or typical antipsychotics...
  28. pmc Fixing the broken system of genetic locus symbols: Parkinson disease and dystonia as examples
    Connie Marras
    Toronto Western Hospital Morton and Gloria Shulman Movement Disorders Centre and the Edmond J Safra Program in Parkinson s Disease, University of Toronto, Toronto, Canada
    Neurology 78:1016-24. 2012
    ....
  29. doi Confounders and intermediaries in case-control study designs: a strategy for distinguishing between the two when measured using the same variable
    Andrea Gruneir
    Women s College Research Institute, Women s College Hospital, Toronto, Ontario, Canada
    Pharmacoepidemiol Drug Saf 20:221-8. 2011
    ....
  30. doi Parkinson's disease subtypes: lost in translation?
    Connie Marras
    Toronto Western Hospital, Movement Disorders Centre, 399 Bathurst St 7 MCL, Toronto, ON M5T 2S8, Canada
    J Neurol Neurosurg Psychiatry 84:409-15. 2013
    ....
  31. doi Genetics meets environment: evaluating gene-environment interactions in neurologic diseases
    Connie Marras
    Toronto Western Hospital, University of Toronto, Ontario, Canada
    Semin Neurol 31:553-61. 2011
    ..Collaborations between genetics and environmental experts will be crucial to understand the complex relationships...
  32. ncbi Predicting motor decline and disability in Parkinson disease: a systematic review
    Connie Marras
    Morton and Gloria Shulman Movement Disorders Center, Toronto Western Hospital, University Health Network, University of Toronto, Ontario, Canada
    Arch Neurol 59:1724-8. 2002
    ..The clinical course of Parkinson disease (PD) varies from patient to patient. A number of studies investigating predictors of prognosis in patients with PD have been performed...
  33. ncbi Unilateral versus bilateral tasks in early asymmetric Parkinson's disease: differential effects on bradykinesia
    Asha Kishore
    Division of Neurology, Department of Medicine, Toronto Western Hospital, Toronto, Ontario, Canada
    Mov Disord 22:328-33. 2007
    ..This observation also highlights the need to perform tasks of bradykinesia in one limb at a time for best accuracy...
  34. doi Invited article: changing concepts in Parkinson disease: moving beyond the decade of the brain
    Connie Marras
    Toronto Western Hospital, University Health Network and University of Toronto, Ontario, Canada
    Neurology 70:1996-2003. 2008
    ..In this article, we highlight important changes in our understanding of PD in six general categories: definition, etiology, pathology, pathogenesis, clinical features, and therapeutics...
  35. pmc Protocol for a systematic review of prognosis after mild traumatic brain injury: an update of the WHO Collaborating Centre Task Force findings
    Carol Cancelliere
    Division of Health Care and Outcomes Research, Toronto Western Research Institute, University Health Network, Ontario, Canada
    Syst Rev 1:17. 2012
    ..Finally, we will identify gaps in the literature, and make recommendations for future research...
  36. ncbi Is there seasonal variation in risk of Parkinson's disease?
    Ronald B Postuma
    Department of Neurology, McGill University, Montreal General Hospital, Montreal, Quebec, Canada
    Mov Disord 22:1097-101. 2007
    ..We found no evidence of systematic seasonal variation in PD incidence by birth date, or of clustering of birth dates during influenza pandemic years in PD patients...
  37. ncbi Re: Cabergoline versus levodopa monotherapy: a decision analysis
    Connie Marras
    Mov Disord 19:736. 2004
  38. ncbi The G2019S LRRK2 mutation in Brazilian patients with Parkinson's disease: phenotype in monozygotic twins
    Renato P Munhoz
    Movement Disorders Unit, Neurology Service, Hospital de Clinicas, Federal University of Parana, Curitiba, PR, Brazil
    Mov Disord 23:290-4. 2008
    ..The clinical presentation of twins was strikingly similar including an identical PD onset at age 60. This observation may suggest that genetic factors predominantly determine age-at-onset...
  39. ncbi A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease
    Cindy Zadikoff
    Department of Neurology, Northwestern University, Parkinson s Disease and Movement Disorders Center, Chicago, Illinois, USA
    Mov Disord 23:297-9. 2008
    ..000002). Compared to the MMSE, the MoCA may be a more sensitive tool to identify early cognitive impairment in PD...
  40. pmc Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study
    Daniel G Healy
    Department of Clinical Neurosciences, Institute of Neurology, University College London, London, UK
    Lancet Neurol 7:583-90. 2008
    ..LRRK2-associated PD be distinguished from idiopathic PD; which mutations in LRRK2 are pathogenic; and what is the age-specific cumulative risk of PD for individuals who inherit or are at risk of inheriting a deleterious mutation in LRRK2?..